Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - avelumabum - konzentrat zur herstellung einer infusionslösung - avelumabum 200 mg, mannitolum, acidum aceticum glaciale, polysorbatum 20, natrii hydroxidum corresp. natrium 1.725 mg, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - merkelzellkarzinom - biotechnologika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

organon healthcare gmbh (1007295) - natriumalendronat (ph.eur.) - tablette - teil 1 - tablette; natriumalendronat (ph.eur.) (26118) 91,37 milligramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - clindamycinhydrochlorid - filmtablette - teil 1 - filmtablette; clindamycinhydrochlorid (03812) 651,5 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - clindamycinhydrochlorid 1 h<2>o - hartkapsel - teil 1 - hartkapsel; clindamycinhydrochlorid 1 h<2>o (07145) 174,2 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - clindamycinhydrochlorid - filmtablette - teil 1 - filmtablette; clindamycinhydrochlorid (03812) 488,7 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - clindamycinhydrochlorid - filmtablette - teil 1 - filmtablette; clindamycinhydrochlorid (03812) 651,5 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - clindamycinhydrochlorid 1 h<2>o - hartkapsel - teil 1 - hartkapsel; clindamycinhydrochlorid 1 h<2>o (07145) 348,4 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

xeolas pharmaceuticals ltd - natrium alendronat - lösung zum einnehmen - 70mg - alendronsäure